Oxidoreductase Type 1/4
| Catalog# | Product Description | Host Species | Nature | Cross reactivity | Quantity | Volume | Price |
|---|---|---|---|---|---|---|---|
| Wwox-101AP | Oxidoreductase Type 1/4 antibodies | Rabbit | AP | m, h | 100.0 ug | 150-500 ul |
$245.00
|
| FITC-Wwox | FITC-conjugated antibodies | Rabbit | FITC-AP | m, h | 100.0 ug | 150-500 ul |
$350.00
|
| P-Wwox | Antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| PC-Wwox | WB positive control for Wwox | n/a | Protein in ready-to-use buffer | n/a | 0.0 ug | 150 ul |
$185.00
|
WW domain-containing oxidoreductase (Wwox) proteins belong to a family of proteins (Wwox 1–Wwox 8) that are involved in regulation of programmed cell death. Human Wwox gene encodes a putative tumor suppressor WW domain-containing oxidoreductase Wwox1 (also known as Wwox or FOR). Wwox expression has been shown in prostate, lung, breast and other cancers. In addition, numerous aberrant Wwox mRNA transcripts have been found in cancer cells. Wwox gene maps to the common fragile site FRA16D on chromosome 16q23.3-24.1, is altered in breast, esophageal, and ovarian cancer (2). Wwox transcripts with missing Wwox exons are noted in 7 primary tumors (7 of 27; 25.9%) and 5 of 8 cell lines. In addition, loss of heterozygosity at the Wwox locus was observed in 10 primary lung tumors (2).
Wwox1 is a pro-apoptotic protein. In response to stress or apoptotic stimuli, WOX1 became phosphorylated at Tyr33, which enabled its complex formation with activated p53 and JNK1. The p53/Wwox1 complex translocated to the mitochondria and further to the nuclei to mediate apoptosis. Wwox1 mutants, which were inactivated for nuclear translocation or Tyr33 phosphorylation, failed to induce apoptosis, indicating that activation of Wwox1 via Tyr33 phosphorylation, followed by nuclear translocation, is essential for inducing cell death. Wwox1 induced apoptosis synergistically with p53. In contrast, transiently activated JNK1 induced anti-apoptotic response, and this protective activity inhibited Wwox1-induced apoptosis. Taken together, Wwox1 is involved in stress and apoptotic responses, and is likely to regulate the activation of both p53 and JNK1. In murine fetuses, WOX1 was present prevalently in the brainstem, spinal cord and peripheral nerve bundles, but its expression decreased after birth. In parallel, the expression of WOX1, as determined by Western blotting, was significantly reduced in the brain stem and spinal cord of adult mice. Notably, high levels of WOX1 immunoreactivity was observed in the neural crest-derived structures such as cranial and spinal ganglia and cranial mesenchyme during the late fetal stage. In the adult brain, WOX1 is abundant in the epithelial cells of the choroids plexus and ependymal cells, while a low to moderate level of WOX1 is observed within white matter tracts, such as axonal profiles of the corpus callosum, striatum, optic tract, and cerebral peduncle (3).
The Wwox1/4-selective antibodies were generated in rabbits against C-terminal peptide that is unique to wwox1 and Wwox 4 proteins. The Wwox1/4 antibody can easily differentiate the two proteins based on their size. These antibodies have been affinity purified and characterized for applications noted in the specification sheet. Other related products include antibodies to SERHL, mucin, p14arf, src, Ras, CAB2, XTP4, Her 2, ACK1 etc. FabGennix Inc. also provides limited quantities of antigenic blocking peptides for Wwox1-101AP antibodies.
For research use only, not for diagnostic or therapeutic use.
Data Sheets
MSDS
General Information
Citations
Search FabGennix Product Citation Data Base
Search